top of page
Profile
Join date: Oct 1, 2020
Posts (49)

Jan 22, 2025 ∙ 2 min
NeuroSigma Announces Patent Application Protecting Use of Trigeminal Nerve Stimulation to Include Treatment of Dyslexia and Other Neurodevelopmental Disorders
LOS ANGELES, January 22, 2024 (GLOBE NEWSWIRE) -- NeuroSigma, Inc. , a Los Angeles-based bioelectronics company commercializing the...
5
0

Jan 13, 2025 ∙ 5 min
Clinical Trial of NeuroSigma’s Monarch eTNS System for ADHD at King’s College London Completes Enrollment.
ATTENS (ADHD trial of external trigeminal nerve stimulation) Project , led by Professor Katya Rubia at the Institute of Psychiatry,...
2
0

Jan 12, 2025 ∙ 6 min
Telix to Acquire Next-Generation Therapeutic Assets and Innovative Biologics Technology Platform(PRNewsfoto/Telix Pharmaceuticals Limited)
MELBOURNE, Australia and INDIANAPOLIS, Jan. 13, 2025 /PRNewswire/ -- Telix Pharmaceuticals Limited (ASX: TLX, Nasdaq: TLX, Telix, the...
5
0
ken4025
Admin
More actions
bottom of page